MarketVIEW: Clostridium difficile vaccines (West)

• Publication date: February 2012
• Report size: 95 pages

Clostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients experience fever, tachycardia and psuedomembranous colitis. Risk factors for C.diff infections are >65 yrs of age, hospitalization, severe underlying illness coupled with chronic antibiotic therapy. Although ...

Clostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients experience fever, tachycardia and psuedomembranous colitis. Risk factors for C.diff infections are >65 yrs of age, hospitalization, severe underlying illness coupled with chronic antibiotic therapy. Although CDAD can be managed usually by stopping antibiotic therapy or the use of metronidazole and vancomycin treatment, patient mortality can still reach 6-30%. In some patients with toxic megacolon who require surgical intervention or colectomy, mortality can reach even higher rates of 35-50%. 

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of C.diff vaccines to 2030 in the major Western markets. All three potential vaccine indications are modelled: Community prophylaxis (PX), Hospital prophylaxis (PX) and preventation of CDI recurrences (TX) with a focus on key target populations and latest predicted profile profiles. Also included is an in-depth epidemiology forecast to 2030 including number of CDI cases per country drawing upon latest surveillance data (pan-European survey). A discussion of the potential impact of latest pipeline developments/launches e.g. Fidoxamicin (OPT-80) and MK-3415A (monoclonals) on the vaccine proposition is covered. 


THIS PRODUCT IS AN EXECUTIVE PRESENTATION + 3 MODELS 

Drug And Medication Industry

Contents – Executive presentation (MS PowerPoint based)
Author’s note
Executive summary
Key commercial outputs: Community PX product
Key commercial outputs: Hospital PX product
Key commercial outputs: prevention of relapses (TX)
Overview of latest changes – February 2012
Epidemiology forecast – latest data
Epidemiology: number of CDI cases (2008-2030)
Epidemiology: incidence per country 2000-2030
Epidemiology: possible scenarios to 2030
C.diff vaccines: Epidemiology: possible scenarios to 2030
C.Diff vaccines: three potential markets modelled
C.Diff vaccines: example target populations
Community prophylaxis: major model assumptions
Prevention of CDI recurrences: major model assumptions
Hospital prophylaxis: major model assumptions
Community prophylaxis: available market ($000s) to 2030
Community prophylaxis: competitor revenues ($000s) to 2030
Prevention of CDI recurrences: available market ($000s) to 2030
Prevention of CDI recurrences: competitor revenues ($000s) to 2030
Hospital prophylaxis: available market ($000s) to 2030
Hospital prophylaxis: competitor revenues ($000s) to 2030
Markets covered to 2030
Pricing assumptions applied
Competitor landscape: overview
Sanofi Pasteur: ACAM-CDIFF
ACAM-CDIFF clinical development plan
Intercell AG: IC84
Antibiotics
Monoclonal antibodies
Epidemiology: situation overview
Acute care hospitals: US
LTCFs: US
Acute care hospitals: pan-European
Acute care hospitals: UK (Scotland, Wales and N.I.)
Acute care hospitals: Germany
Acute care hospitals: France
Acute care hospitals: Spain
Acute care hospitals: Italy
Acute care hospitals: Canada
Acute care hospitals: Australia
Epidemiology: forecast trends
Definitions of CDI exposures
Follow-on vaccines: market share analysis
Bibliography
Disclaimer
About VacZine Analytics
PAGES: ~95 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model(s) (MS Excel-based)
Note: Three models are included with this product
Hospital vaccination (PX)
Community vaccination (PX)
Prevention of CDI replases (TX)
United States
Canada
UK
France
Germany
Italy
Spain
Other EU